Abstract: The present invention provides nucleic acids and amino acids for novel olfactory receptors as well as methods for identifying olfactory receptors. More specifically, the present invention provides nucleic acids and amino acids for novel olfactory receptors in Drosophila as well as methods of using the provided nucleic acids and amino acids. In addition, this invention provides methods of identifying ligands which bind to the novel olfactory receptors as well as a variety of methods for using the ligands so identified.
Type:
Grant
Filed:
January 25, 2000
Date of Patent:
August 26, 2003
Assignee:
Yale University
Inventors:
John R. Carlson, Junhyong Kim, Peter J. Clyne, Coral G. Warr
Abstract: Bovine respiratory disease (BRD) complex, shipping fever, or pneumomic pasteurellosis, is a multifactorial disease whereby a combination of viral infection, adverse environment and poor immune status may combine to predispose animals to bacterial infections. The exotoxin, or leukotoxin (Lkt), may contribute to pathogenesis by impairing the primary lung defenses and subsequent immune responses or by causing inflammations as a result of leukocyte lysis. The present invention provides a modified microorganism which produces an Lkt toxin, wherein said Lkt toxin is partially or fully inactivated. In a further embodiment of the present invention, there is provided a modified microorganism wherein an Lkt toxin operon including an Lkt structural gene and/or a post transational activator of the organism is partially or fully inactivated. The present applicants have found that a precursor of Lkt toxin has reduced toxic activity.
Type:
Grant
Filed:
June 23, 1998
Date of Patent:
August 26, 2003
Assignees:
Commonwealth Scientific and Industrial Research
Organisation, The State of Queensland Through its Department of Primary
Industries, The State of New South Wales Through its Department of
Agriculture, The University of New England of Armidale
Inventors:
Christopher Thomas Prideaux, Adrian Leslie Mark Hodgson
Abstract: Isolated DNA molecules encoding at least one epitope of the Mi-2 antigen and at least one epitope of the PM-Scl antigen are provided. The DNA may be used as probes to obtain related DNA. Proteins expressed from the DNA may be used in assays for the diagnosis of dermatomyositis and polymyositis, particularly polymyositis-scleroderma overlap disorders. The expressed proteins may also be used for purification of the associated autoantigens.
Type:
Grant
Filed:
September 9, 1992
Date of Patent:
August 26, 2003
Assignees:
Board of Regents of the University of Oklahoma, Oklahoma Medical Research Foundation
Abstract: Substituted condensation products of N-benzyl-3-indenylacetamides with heterocyclic aldehydes are useful for inducing or promoting apotosis and for arresting uncontrolled neoplastic cell proliferation, and are specifically useful in the arresting and treatment of neoplasias, including precancerous and cancerous lesions.
Type:
Grant
Filed:
July 26, 2002
Date of Patent:
August 26, 2003
Assignees:
Cell Pathways, Inc., University of Arizona
Inventors:
Gerhard J. Sperl, Paul Gross, Klaus Brendel, Gary A. Piazza, Rifat Pamukcu
Abstract: Methods for treating vascular conditions associated with localized imbalance in vascular tone, which are hypothesized to be largely due to elevated endothelin (ET) are provided. The methods involve administration of nitric oxide (NO), agents which are able to provide NO, such as NO donors, agents which activate guanyl cyclase, such as YC-1, or agents which prolong the actions of endogenous NO or cyclic guanosine monophosphate (cGMP; a 2nd messenger molecule), such as phosphodiesterase (PDE) inhibitors. According to the invention, such agents are administered in minimal doses or microdoses by any route known in the art, so as to provide dosages which are about one half to about one twentieth (½ to {fraction (1/20)}) of those known to induce vasodilation in “normal” circulations.
Type:
Grant
Filed:
March 8, 2002
Date of Patent:
August 26, 2003
Assignee:
Queen's University at Kingston
Inventors:
Michael A. Adams, Jeremy P. W. Heaton, James D. Banting
Abstract: This invention provides a method of inhibiting an autoimmune response in an animal suffering from an autoimmune disease selected from the group consisting of psoriasis, Lyme disease and hyper IgE syndrome which comprises administering to the animal, in an amount effective to treat the autoimmune disease, an antibody that binds specifically to a protein specifically recognized by monoclonal antibody 5c8 produced by the hybridoma having ATCC Accession No. HB 10916.
Type:
Grant
Filed:
October 20, 1994
Date of Patent:
August 26, 2003
Assignee:
The Trustees of Columbia University in the City of New
York
Inventors:
Seth Lederman, Leonard Chess, Michael J. Yellin
Abstract: An optical fiber amplifier utilizing a phosphate glass optical fiber highly doped with rare-earth ions such as erbium to exhibit high gain per unit length, enabling the use of short fiber strands to achieve the needed gain in practical fiber optical communication networks. The high-gain phosphate optical glass fiber amplifiers are integrated onto substrates to form an integrated optics amplifier module. An optical pump such as a semiconductor laser of suitable wavelength is used to promote gain inversion of erbium ions and ultimately provide power amplification of a given input signal. Gain inversion is enhanced in the erbium doped phosphate glass fiber by co-doping with ytterbium. A phosphate fiber amplifier or an integrated optics amplifier module utilizing this power amplification can be combined with other components such as splitters, combiners, modulators, or arrayed waveguide gratings to form lossless or amplified components that do not suffer from insertion loss when added to an optical network.
Type:
Grant
Filed:
June 9, 2000
Date of Patent:
August 26, 2003
Assignee:
The Arizona Board of Regents on behalf of the University of
Arizona
Abstract: The present invention provides a method for the identification of a pattern of changes in cellular responses induced by the selective inhibition of a signaling molecule, by determining the specific effects of a selective inhibitor on a mutant form of a signaling molecule on cellular responses. The pattern of alterations in cellular responses resulting from the inhibition by a selective mutant inhibitor of the mutant signaling molecule are characteristic of the cellular response alterations that a specific inhibitor of the wild-type signaling molecule will produce. After determining the pattern of cellular responses of the mutant cells with the mutant molecule, compounds may be identified capable of inhibiting the wild-type molecule by producing a pattern of cellular responses in wild-type cells matching or having similarity to that of the inhibition of the mutant molecule.
Abstract: The present invention provides a sensitive test for objectively diagnosing the presence of Didymella bryoniae, the causative agent of gummy stem blight, and differentiating it from similar, nonpathogenic Phoma species. The assay is applicable to DNA isolated from extracts from plant leaves, stem or seed. The detection method employs a polymerase chain reaction technique, using specific oligonucleotide primers for amplification. PCR Products can be visualized using an ELISA-based calorimetric detection system.
Type:
Grant
Filed:
January 10, 2001
Date of Patent:
August 26, 2003
Assignee:
Clemson University
Inventors:
Anthony P. Keinath, Benesh M. Somai, Ralph A. Dean
Abstract: A system and apparatus for controlled fusion in a field reversed configuration (FRC) magnetic topology and conversion of fusion product energies directly to electric power. Preferably, plasma ions are magnetically confined in the FRC while plasma electrons are electrostatically confined in a deep energy well, created by tuning an externally applied magnetic field. In this configuration, ions and electrons may have adequate density and temperature so that upon collisions they are fused together by the nuclear force, thus forming fusion products that emerge in the form of an annular beam. Energy is removed from the fusion product ions as they spiral past electrodes of an inverse cyclotron converter. Advantageously, the fusion fuel plasmas that can be used with the present confinement and energy conversion system include advanced (aneutronic) fuels.
Type:
Grant
Filed:
February 14, 2002
Date of Patent:
August 26, 2003
Assignees:
The Regents of the University of California, University of Florida Research Foundation
Abstract: Rev-caspases comprising a primary product in which the small subunit is N-terminal to the large subunit are provided. Rev-caspases are used for screening and identifying caspase inhibitors and enhancers. Rev-caspase genes can be delivered to cells for gene therapy.
Abstract: Novel transferrin binding proteins from Pasteurella haemolytica, and nucleic acid molecules encoding the novel proteins are disclosed. Antibodies against the novel proteins are disclosed. The invention also relates to vaccines containing the novel proteins of the invention. The invention also provides methods for identifying substances which affect the binding of transferrin to the proteins and methods for screening for agonists or antagonists of the binding of the proteins and transferrin.
Type:
Grant
Filed:
November 29, 1996
Date of Patent:
August 26, 2003
Assignees:
University Technologies International, Inc., University of Guelph, University of Saskatchewan
Inventors:
Reggie Y. C. Lo, Anthony Bernard Schryvers, Andrew Allan Potter
Abstract: Methods are disclosed for rapid, reliable and simple isolation of RNA, DNA and proteins from formalin-fixed paraffin-embedded tissue samples. RNA purified in this manner can be used to monitor gene expression levels. The tissue sample can be a tumor or other pathological tissue.
Type:
Grant
Filed:
March 1, 2001
Date of Patent:
August 26, 2003
Assignee:
University of Southern California
Inventors:
Kathleen Danenberg, Peter V. Danenberg, Steven Swenson
Abstract: For the early detection of blindness-causing diabetic retinopathy, an apparatus for measuring the autofluorescence of the cornea of an eye, comprising means for tangentially illuminating the cornea, means for receiving the autofluorescent radiation generated in the cornea by this illumination, and means for processing the measured autofluorescent radiation, wherein the means for tangentially illuminating the cornea comprises at least one light source which radiates blue light and at least one filter which transmits at least a part of the blue light in a light path to the cornea, and the means for receiving the autofluorescent radiation generated in the cornea comprises at least one filter which transmits green light.
Abstract: Material droplet generator systems utilizing single-wire arc spray apparatus and methods are provided. In some embodiments, the apparatus include a single consumable, first wire electrode fed through a gas nozzle and a non-consumable, second electrode outside of and proximate a nozzle exit. In some embodiments, the second electrode may have at least a terminal or end portion having an axis that is oriented substantially perpendicular to an axis of the gas nozzle. The first wire electrode may form an angle of 5 degrees or less with the axis of the gas nozzle. Preferably, the first wire electrode forms an anode while the second electrode forms a cathode. In operation, the apparatus and methods produce a narrow beam thermal spray, which, when deposited upon a substrate surface, results in a high definition spray pattern and coating having distinct boundaries and a controllable thickness.
Type:
Grant
Filed:
April 26, 2001
Date of Patent:
August 26, 2003
Assignee:
Regents of the University of Minnesota
Inventors:
Richard R. Carlson, Joachim V. R. Heberlein
Abstract: Nucleic acid and amino acid sequences of the Omp85 proteins of N. gonorrhoeae and N. meningitidis, and fragments thereof are useful in vaccine compositions, therapeutic compositions and diagnostic compositions for use in the prevention, treatment and diagnosis of non-symptomatic gonococcal infection or symptomatic disease and non-symptomatic meningococcal infection and symptomatic disease. Antibodies are developed to these proteins and also useful in the compositions and methods described herein.
Abstract: Methods and systems for backlash compensation. Restrictive assumptions on the backlash nonlinearity (e.g. the same slopes of the lines, etc.) are not required. The compensator scheme has dynamic inversion structure, with a neural network in the feedforward path that approximates the backlash inversion error plus filter dynamics needed for backstepping design. The neural network controller does not require preliminary off-line training. Neural network tuning is based on a modified Hebbian tuning law, which requires less computation than backpropagation. The backstepping controller uses a practical filtered derivative, unlike the usual differentiation required by earlier backstepping routines. Rigorous stability proofs are given using Lyapunov theory. Simulation results show that the proposed compensation scheme is an efficient way of improving the tracking performance of a vast array of nonlinear systems with backlash.
Type:
Grant
Filed:
April 20, 2000
Date of Patent:
August 26, 2003
Assignee:
Board of Regents, The University of Texas System
Inventors:
Rastko R. Selmic, Frank L. Lewis, Anthony J. Calise, Michael B. McFarland
Abstract: This invention relates to rotary pumps adapted, but not exclusively, for use as artificial hearts or ventricular assist devices and, in particular, discloses in preferred forms a seal-less shaft-less pump featuring open or closed (shrouded) impeller blades with the edges of the blades used as hydrodynamic thrust bearings and with electromagnetic torque provided by the interaction between magnets embedded in the blades and a rotating current pattern generated in coils fixed relative to the pump housing.
Type:
Grant
Filed:
December 11, 2000
Date of Patent:
August 26, 2003
Assignees:
Ventrassist Pty Ltd, University of Technology Sydney
Inventors:
John Campbell Woodard, Peter Andrew Watterson, Geoffrey Douglas Tansley
Abstract: A method and apparatus for increasing the signal-to-noise ratio in a range of mass-to-charge ratios of a mass spectrum. Initially ions of interest and background ions having mass-to-charge ratios within the range of mass-to-charge ratios are generated. The ions of interest and the background ions are then subjected to an activation energy sufficient to cause dissociation of background ions to an extent greater than the dissociation of the ions of interest. The dissociation of the background ions causes the background ions to have mass-to-charge ratios that fall outside of the range of mass-to-charge ratios. The mass-to-charge ratios of the ions of interest are then detected.